Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
brogidirsen
- Development stage
- Phase 2
- Lead developer
- Nippon Shinyaku
- Modality
- Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, MicroRNA (miRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Single-strand DNA → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Modified DNA Oligonucleotides → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Intravenous
01
Overview
Brogidirsen is an investigational antisense oligonucleotide designed as a dual-targeting phosphorodiamidate morpholino oligomer (PMO) for the treatment of Duchenne muscular dystrophy (DMD) in patients with mutations amenable to exon 44 skipping. It contains two linked sequences that bind to separate sites within exon 44 of the DMD gene, promoting exon skipping and enabling production of partially functional dystrophin protein. Brogidirsen is administered intravenously and has demonstrated dose-dependent increases in dystrophin expression and stabilization or improvement in motor function in early-phase clinical trials. The drug has received FDA Breakthrough Therapy, Orphan Drug, and Rare Pediatric Disease designations[2][3][5][8].
- Other names
- brogidirsenNS-089/NCNP-02
02
Targets
DMD (Dystrophin)
Beyond the preview
Go deeper on brogidirsen.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on brogidirsen.